Put companies on watchlist
SHOP APOTHEKE EUROPE N.V.
ISIN: NL0012044747
WKN: A2AR94
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

SHOP APOTHEKE EUROPE N.V. · ISIN: NL0012044747 · EQS - adhoc news (114 News)
Country: Netherlands · Primary market: Netherlands · EQS NID: 1638825
22 May 2023 10:59PM

Termination of voting pool agreement.


EQS-Ad-hoc: SHOP APOTHEKE EUROPE N.V. / Key word(s): Miscellaneous
Redcare Pharmacy N.V. (formerly SHOP APOTHEKE EUROPE N.V.): Termination of voting pool agreement.

22-May-2023 / 22:59 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Redcare Pharmacy N.V. (formerly SHOP APOTHEKE EUROPE N.V.): Termination of voting pool agreement.

Sevenum, the Netherlands, 22 May 2023. Redcare Pharmacy N.V. (formerly SHOP APOTHEKE EUROPE N.V.) has been informed today that the pool agreement of 25 individual shareholders, who at the time of its formation controlled more than 26% of the voting rights, has been terminated due to a recent dilution of their shareholding. The dilution resulted from the capital increase in connection with the formation of a joint venture with Galenica. Subsequently, the shareholding of the pool fell below the threshold of 25% of the total voting rights.

Notwithstanding the dissolution of the pool agreement, the 25 individual shareholders around and including the company's founder Michael Köhler have reaffirmed their continued support for Redcare Pharmacy N.V.

 

Contact:

rikutis consulting
Thomas Schnorrenberg
Mobil: +49 151 46 53 13 17
E-Mail: presse@shop-apotheke.com



End of Inside Information

22-May-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SHOP APOTHEKE EUROPE N.V.
Erik de Rodeweg 11-13
5975 WD Sevenum
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: Investor.Relations@shop-apotheke.com
Internet: www.shop-apotheke-europe.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y07
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1638825

 
End of Announcement EQS News Service

1638825  22-May-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1638825&application_name=news&site_id=boersengefluester
Visual performance / price development - SHOP APOTHEKE EUROPE N.V.
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.